{'fraction_non_alphanumeric': 0.03471074380165289, 'fraction_numerical': 0.019834710743801654, 'mean_word_length': 5.274611398963731, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Construction of the HBV S‐ecdCD40L fusion gene and effects of HBV S‐ecdCD40L modification on function of dendritic cells

Summary.  We examined the effect of dendritic cells engineered to express an HBV S antigen CD40L fusion gene (HBV S‐ecdCD40L). The DNA of HBV S gene and the cDNA of the extracellular domain of human CD40 ligand were linked by cloning. Peripheral blood mononuclear cells (PBMC) from healthy adults were incubated and induced into dendritic cells (DC) in presence of granulocyte/macrophage colony‐stimulating factor (GM‐CSF) and interleukin‐4(IL‐4). The DCs were transfected the novel construct, and the impact of the expressed clone assessed. We find that, compared with control groups, modification of DCs with HBV S‐ecdCD40L fusion gene resulted in the activation of DCs with upregulated expression of immunologically important cell surface molecules (CD80, CD86 and HLA‐DR) and proinflammatory cytokines (IL‐12). The DCs modified with HBV S‐ecdCD40L are able to stimulate enhanced allogeneic T‐cell proliferation in vitro. Thus, the fusion gene HBV S‐ecdCD40L can promote DC’s activation and enhance its function and may prove to be the foundation for a new type of hepatitis B vaccine.